Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigational Varicella Vaccine (VNS) vs Varivax in Healthy Children 12-15 Months
NCT06740630Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of Investigational varicella vaccine in chickenpox (5 arms), sponsored by GSK. Primary endpoints: Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti-glycoprotein E (gE) Immunoglobulin (IgG) at Day 43 and Geometric Mean Concentration (GMC) of anti-VZV gE IgG at Day 43. Started Jan 2025; status: recruiting.
02
Drugs
Investigational varicella vaccine
03
Conditions
chickenpox
Beyond the preview
Go deeper on NCT06740630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740630.